238.09 0.00 (0.00%)
After hours: 5:01PM EDT
|Bid||0.00 x 1000|
|Ask||0.00 x 900|
|Day's Range||237.28 - 240.92|
|52 Week Range||203.99 - 265.87|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||97.62|
|Earnings Date||Nov 6, 2018|
|Forward Dividend & Yield||3.00 (1.25%)|
|1y Target Est||272.44|
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
As we discussed in the previous part, Wall Street analysts expect Thermo Fisher Scientific (TMO) to report 11.5% revenue growth to $5.70 billion during the third quarter. Thermo Fisher provides products and services through its brands including Thermo Scientific, Fisher Scientific, Invitrogen, Unity Lab Services, and Applied Biosystems.
NEW YORK,, Oct. 19, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
FRANKLIN LAKES, N.J., Oct. 17, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced a donation of 20 million syringes valued at $1 million to Rotary, a nonprofit organization dedicated to tackling the world's most pressing humanitarian challenges, in support of the Global Polio Eradication Initiative. With facilitation by Direct Relief, a global humanitarian aid organization, the 20 million syringes will be delivered and used for vaccinations in four states within India — Maharashtra, West Bengal, Tamil Nadu and Haryana — towards the goal of sustaining polio eradication in India, which was first achieved in 2014. "Rotary has been one of the leaders in the global effort to eradicate polio for years, and with this donation, BD is linking back to the contribution the company made many years ago to the original polio eradication effort in the U.S.," said Gary Cohen, executive vice president of Global Health at BD and president of the BD Foundation.
BD MAX™ MDR-TB Panel Obtains CE-IVD Status in Europe FRANKLIN LAKES, N.J. , Oct. 16, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today ...
How Is Medtronic Positioned in October? On October 12, Medtronic stock closed at $94.69, which is a ~1.7% rise from its prior-day close of $93.11 on October 11 and a ~24% rise from its 52-week low of $76.41. Medtronic hit its 52-week high of $100.15 on September 26, 2018.
Jim Cramer rattles off his take on callers' favorite stocks, including a biotech play that's ripe for the picking.
Figuring out which healthcare stocks to buy has never been an easy task. President Trump has repeatedly blasted the Affordable Care Act, promising to overhaul our healthcare system. Naturally, many healthcare stocks have experienced a tumultuous ride in the markets under the Trump White House.
FRANKLIN LAKES, N.J. , Oct. 3, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year ...
TEMPE, Ariz., Oct. 3, 2018 /PRNewswire/ -- Officials from BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, were joined today by Gov. Doug Ducey, Tempe Mayor Mark Mitchell and representatives of The Boyer Company to officially break ground on the new I.D.E.A. (Innovation, Discovery, Education and Arts) Tempe campus. BD Peripheral Intervention will be the first business to move to the new campus that is focused on attracting new technology companies to Tempe.
FRANKLIN LAKES, N.J., Oct. 3, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (BDX), a leading global medical technology company, today announced that Tom Polen will add the responsibility of chief operating officer of BD, in addition to his current role as president. As president and chief operating officer, Polen will have oversight of BD's three operating segments, its innovation and new product development pipeline, and global operations for the company, including all manufacturing facilities and supply chain operations. "Tom's promotion reflects his leadership role developing and implementing BD's strategy and vision and aligning our businesses under three strong segment leaders," said Forlenza.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 1) Abbott Laboratories (NYSE: ABT ) AstraZeneca plc (NYSE: ...
The new 120,000-square-foot building will serve as the New Jersey company's southwest headquarters, housing employees from a medical supplier that was acquired last year.
Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as Becton Dickinson and Company (NYSE:BDX) a safer option. Doing business globally, large caps tend toRead More...
On September 13, Abbott Laboratories (ABT) announced its 379th consecutive quarterly dividend, which is payable on November 15. The dividend of $0.28 per share will be paid to shareholders of record as of the close of business on October 15. The company’s annual dividend in 2017 was $1.06, while its indicated annual dividend for 2018 is $1.12 per share. Last year, it paid a quarterly dividend of $0.265 to its shareholders, so its new quarterly dividend represents an increase of ~5.7%.
Thermo Fisher Scientific (TMO) operates in four business segments. The Analytical Instruments segment provides instruments, software, and services for use in laboratory applications. The segment’s revenue rose from $1.17 billion in the second quarter of 2017 to $1.31 billion in the second quarter of 2018 due to increased demand for chromatography and mass spectrometry and electron microscopy. This increase came from the strong performance of the healthcare market channel and clinical diagnostic products.
Wall Street analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017. Its adjusted EPS is estimated at $4 in 2018 compared to $3.32 in 2017. Analysts estimate that its net adjusted income will increase to $693.4 million in 2018 compared to $634.9 million in 2017.